Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Angiogenesis
Research from J. Matsui and colleagues provide new insights into angiogenesis
April 8th, 2008
"E7080 is an orally active inhibitor of multiple receptor tyrosine kinases including VEGF, FGF and SCF receptors. In this study, we show the inhibitory activity of E7080 against SCF-induced angio-genesis in vitro and tumor growth of SCF-producing human small cell lung carcinoma H146 cells in vivo," scientists writing in the International Journal of Cancer report. "E7080 inhibits SCF-driven tube formation of HUVEC, which express SCIF receptor, KIT at the IC50 value of 5.2 nM and it was almost identical for VEGF-driven one (IC50 = 5.1 nM). To assess the role of SCF/KIT signaling in tumor angiogenesis, we evaluated the effect of imatinib, a selective KIT kinase...
Source: Cancer Weekly (2008-04-08)
|
